NCT04808791 - iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 27, 2021

Primary Completion Date

July 7, 2023

Study Completion Date

July 21, 2023

Conditions

Gastroesophageal Junction AdenocarcinomaAdvanced Gastric Carcinoma

Interventions

DRUG

Irinotecan

"Irinotecan is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase I inhibitor."

DRUG

Oxaliplatin

"Oxaliplatin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Oxaliplatin is classified as an alkylating agent."

DRUG

TAS 102 (Trifluridine/Tipiracil)

"Trifluridine/Tipiracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an antimetabolite/pyrimidine analog; antimetabolite/thymidine phosphorylase inhibitor"

Trial Locations (1)

Unknown

Cross Cancer Institute, Edmonton

All Listed Sponsors

lead

AHS Cancer Control Alberta

OTHER